Omeros Slumps As FDA Extends Decision Date For Narsoplimab

Shares of Omeros Corp. (OMER) are down more than 16% Thursday, following news related to its lead drug candidate Narsoplimab.

from RTT - Top Story https://ift.tt/3u99lrb
via IFTTT